Personal information

Websites & social links

ResearchGate

Other IDs

Scopus Author ID: 57188680830

Countries

Poland

Activities

Collapse all

Employment (1)

Maria Sklodowska-Curie National Research Institute of Oncology: Gliwice, PL

2018-05-02 to present (Department of Clinical and Molecular Genetics)
Employment
Source: Self-asserted source
Patrycja Tudrej

Education and qualifications (3)

Maria Sklodowska-Curie National Research Institute of Oncology: Gliwice, PL

2014-10-01 to 2021-03-08 | PhD studies in medical biology (Center for Translational Research and Molecular Biology of Cancer)
Education
Source: Self-asserted source
Patrycja Tudrej

Medical University of Silesia: Katowice, PL

2015-10-01 to 2017-03-31 | Laboratory Diagnostican (Department of Pharmacy with the Division of Laboratory Medicine)
Education
Source: Self-asserted source
Patrycja Tudrej

University of Silesia: Katowice, PL

2008-10-01 to 2013-06-30 | MSc in Biotechnology (Department of Biology and Environmental Protection)
Education
Source: Self-asserted source
Patrycja Tudrej

Professional activities (1)

Bonnier Buisness Polska sp. z o.o. : Warszawa, PL

2018-10-10 to 2018-10-10 | 3rd place in the competition "Złoty Skalpel"
Distinction
Source: Self-asserted source
Patrycja Tudrej

Funding (2)

Ocena metylacji promotora genu ESR1 u pacjentek z przerzutowym ER(+)/HER2(-) rakiem piersi po leczeniu inhibitorami aromatazy w kombinacji z rybocyklibem

2021-12 to 2022-12 | Grant
NCN (Kraków, PL)
Source: Self-asserted source
Patrycja Tudrej

Detekcja komórek o fenotypie macierzystym w stabilnych liniach komórkowych raka jajnika

2019-01 to 2021-06 | Grant
Maria Sklodowska-Curie National Research Institute of Oncology (Gliwice, PL)
Source: Self-asserted source
Patrycja Tudrej

Works (6)

Characteristics of in vitro model systems for ovarian cancer studies

Oncology in Clinical Practice
2019 | Journal article
DOI: 10.5603/OCP.2019.0024
Source: Self-asserted source
Patrycja Tudrej

Characteristics of in vivo model systems for ovarian cancer studies

Diagnostics
2019 | Journal article
DOI: 10.3390/diagnostics9030120
EID:

2-s2.0-85072603197
Contributors: Tudrej, P.; Kujawa, K.A.; Cortez, A.J.; Lisowska, K.M.
Source: Self-asserted source
Patrycja Tudrej via Scopus - Elsevier
grade
Preferred source (of 3)‎

Advances in ovarian cancer therapy

Cancer Chemotherapy and Pharmacology
2018 | Journal article
DOI: 10.1007/s00280-017-3501-8
EID:

2-s2.0-85038086728
Contributors: Cortez, A.J.; Tudrej, P.; Kujawa, K.A.; Lisowska, K.M.
Source: Self-asserted source
Patrycja Tudrej via Scopus - Elsevier

Establishment and characterization of the novel high-grade serous ovarian cancer cell line OVPA8

International Journal of Molecular Sciences
2018 | Journal article
DOI: 10.3390/ijms19072080
EID:

2-s2.0-85050361292
Contributors: Tudrej, P.; Olbryt, M.; Zembala-Nożyńska, E.; Kujawa, K.A.; Cortez, A.J.; Fiszer-Kierzkowska, A.; Pigłowski, W.; Nikiel, B.; Głowala-Kosińska, M.; Bartkowska-Chrobok, A. et al.
Source: Self-asserted source
Patrycja Tudrej via Scopus - Elsevier

Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation

Investigational New Drugs
2017 | Journal article
DOI: 10.1007/s10637-017-0465-9
EID:

2-s2.0-85017515667
Contributors: Olbryt, M.; Rusin, A.; Fokt, I.; Habryka, A.; Tudrej, P.; Student, S.; Sochanik, A.; Zieliński, R.; Priebe, W.
Source: Self-asserted source
Patrycja Tudrej via Scopus - Elsevier

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival

Journal of Cancer Research and Clinical Oncology
2016 | Journal article
DOI: 10.1007/s00432-016-2147-y
EID:

2-s2.0-84962248052
Contributors: Lisowska, K.M.; Olbryt, M.; Student, S.; Kujawa, K.A.; Cortez, A.J.; Simek, K.; Dansonka-Mieszkowska, A.; Rzepecka, I.K.; Tudrej, P.; Kupryjańczyk, J.
Source: Self-asserted source
Patrycja Tudrej via Scopus - Elsevier
How many people are using ORCID?